Sentiment Summary
Recent Events
Extraordinary shareholders' meeting to appoint a former Financial Supervisory Service (FSS) official as a new outside director on June 30, 2026. Low importance is estimated as board changes typically have minimal immediate price impact, scheduled.
The company's quarterly earnings report is scheduled for May 18, 2026; a 5-10% price impact is estimated based on historical volatility, scheduled.
Q1 2026 earnings release on May 18, 2026. Low importance is estimated as the announcement of the release date itself usually results in minimal price movement, scheduled.
Celltrion is scheduled to announce its Q1 2026 earnings on May 8, 2026. Analysts forecast consolidated sales of approximately 1.12 trillion KRW and an operating profit of around 314 billion KRW, which is estimated to have a medium market impact (≥5%) scheduled.
The company's labor union has threatened its first-ever general strike to begin on May 1, 2026, following the breakdown of wage negotiations. Analysts forecast a price impact of over 10% due to significant operational risks, expected.
Celltrion applied for marketing authorization to the European Medicines Agency (EMA) for 'Herzuma SC', a subcutaneous formulation of its breast cancer biosimilar Trastuzumab, on April 30, 2026. This first-in-class formulation is estimated to have a high market impact (≥10%) due to its significant competitive advantage.
Yuhan Corp. announced Q1 2026 earnings. Consolidated revenue was KRW 526.8B (+7.2% YoY) and operating profit was KRW 8.8B (+37.3% YoY). Operating profit missed market expectations due to the delayed recognition of a milestone payment for Lazertinib. Due to the earnings miss, a ~5% price impact is expected.
Announced Q1 2026 results: Revenue KRW 392.9B (+0.5% YoY), Operating Profit KRW 53.6B (-9.1% YoY), Net Profit KRW 51.1B (+14.4% YoY). The operating profit decline was attributed to a one-off base effect from prior year's clinical trial material supply.
Announced a strategic partnership with Eli Lilly on April 30, 2026, to launch 'C-Lab Outside,' an open innovation center scheduled for completion in July 2027. Analysts forecast a price impact of approximately 5%, forecasted.
Signed a strategic cooperation agreement with DingTalk (an Alibaba company) to upgrade its operations with artificial intelligence applications. This operational partnership is estimated to have a low market impact (≥1%).
On April 30, 2026, the board of directors announced its proposal to appoint KPMG as the new auditor, replacing Ernst & Young, subject to shareholder approval. Importance is Low as auditor changes typically result in a minor market reaction of approximately 1%.
Announced that its SSS68 injection, a dual-target antibody for APRIL/BAFF, received IND approval from China's NMPA for three autoimmune disease indications; high importance estimated due to the significant clinical potential of the dual-target antibody in three indications, expected.
NDA for sovleplenib for wAIHA accepted and granted priority review by China's NMPA on April 29, 2026; medium importance as regulatory milestones of this nature typically result in a 5-10% price impact, expected.
The company officially appointed Park Se-jin as the new CEO on April 29, 2026, following a pre-announcement on April 28, 2026; a 5-10% price impact is expected due to the leadership transition, expected.
On 2026-04-29, shareholders approved the plan to issue RMB-denominated shares and list on the Shanghai Stock Exchange's Sci-Tech Board (STAR Market). This expansion into mainland capital markets is estimated to have a medium market impact (≥5%) due to improved liquidity.
Directors Tian Zhoushan and Li Dakui retired from the board on 2026-04-29; Low importance justified by minimal expected market impact from board personnel changes, scheduled.
Ex-dividend date for the 2025 final cash dividend of RMB 2 per 10 shares on April 29, 2026; approved at the AGM on April 16, 2026. The dividend amount suggests a >=1% price impact scheduled.
Announced Q1 2026 product revenue exceeded RMB 3.8 billion, a year-over-year increase of over 50%, driven by strong performance of its oncology and general biomedicine portfolios. The stock rose over 4.5% on the news.
Received two clinical trial approvals from China's NMPA for its self-developed Class 1 innovative drug, HS-10522 tablets, for the treatment of uncontrolled hypertension and primary aldosteronism.
The B7-H3 targeted antibody-drug conjugate (ADC) HS-20093 was granted Breakthrough Therapy Designation by China's NMPA for the treatment of advanced castration-resistant prostate cancer.
Partner Compass Therapeutics announced on April 27 that the Phase 2/3 trial for biliary tract cancer drug Tovecimig (ABL001) met its Progression-Free Survival (PFS) endpoint but failed to meet the key Overall Survival (OS) endpoint. The news led to a stock price decline of over 20%.
Announced Q1 2026 results, reporting revenue of CNY 656.2 million (+24.8% YoY) and a net profit of CNY 328 million, a swing to profitability from a loss of CNY 254 million in Q1 2025; high impact expected due to significant financial turnaround.
China's CDE proposed including IBI363, a first-in-class PD-1/IL-2α bispecific antibody, for breakthrough therapy designation for the treatment of advanced MSS/pMMR colorectal cancer. This regulatory progress is estimated to have a medium market impact (≥5%).
Ivonescimab (PD-1/VEGF bispecific antibody) received multiple Class I recommendations in the 2026 Chinese Society of Clinical Oncology (CSCO) Guideline for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) on 2026-04-28. Market impact is estimated at Medium because of the drug's significant role in the first-line NSCLC market.
On 2026-04-28, InnoCare announced the first patient has been dosed in its Phase III registrational clinical trial for Orelabrutinib for the treatment of systemic lupus erythematosus (SLE). This clinical milestone is estimated to have a ~5% price impact as it advances a key pipeline asset.
Announced the presentation of 9 anti-cancer new drug candidate studies at the American Association for Cancer Research (AACR) 2026, showcasing R&D capabilities in next-generation modalities like TPD, mRNA, and ADCs.
Announced on 2026-04-28 that its TUL321 capsule received Investigational New Drug (IND) approval for clinical trials from the U.S. FDA; this regulatory milestone is estimated to have a >1% positive price impact, scheduled.
Reported strong Q1 2026 financial results on April 27, 2026, with revenue of CNY 12.44 billion (+28.8% YoY) and adjusted non-IFRS net profit of CNY 4.60 billion (+71.7% YoY), beating expectations and causing a significant share price increase.
Announced unaudited Q1 2026 financials for subsidiary CSPC Innovation on 2026-04-27, showing a 40.82% revenue increase but a 248.88% widening of net loss; a ~5% price impact is estimated due to mixed subsidiary performance.